Orbus Therapeutics, Inc.   Report issue

For profit Phase 3
Founded: Palo Alto CA United States (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2016
NCT02796261
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

eflornithine (ornidyl) (1 trial)

lomustine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astrocytoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2